JHIU
PTCT icon

Janus Henderson Investors US’s PTC Therapeutics PTCT Stock Holding History

Janus Henderson Investors US’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-722,415
Closed -$23.4M – 1194
2015
Q4 		$23.4M Sell
722,415
-175,906
-20% -$5.18M 0.02% 577
2015
Q3 		$24M Buy
898,321
+60,998
+7% +$2.61M 0.02% 568
2015
Q2 		$40.3M Buy
837,323
+170,059
+25% +$9.92M 0.03% 480
2015
Q1 		$40.6M Buy
667,264
+59,110
+10% +$3.61M 0.03% 502
2014
Q4 		$31.5M Buy
608,154
+40,807
+7% +$1.8M 0.03% 529
2014
Q3 		$25M Buy
567,347
+5,691
+1% +$178K 0.02% 543
2014
Q2 		$14.7M Sell
561,656
-48,765
-8% -$1.04M 0.01% 604
2014
Q1 		$16M Buy
610,421
+163,270
+37% +$4.39M 0.01% 586
2013
Q4 		$7.59M Buy
447,151
+5,190
+1% +$91.2K 0.01% 712
2013
Q3 		$9.48M Buy
+441,961
New +$7.68M 0.01% 657

Other funds holding PTCT

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Janus Henderson Investors US's PTCT Position: Q1 2016 in Review

Janus Henderson Investors US sold out of PTC Therapeutics (PTCT) in Q1 2016, closing a stake of 722,415 shares — an estimated $23.4M sold.

Janus Henderson Investors US first reported a position in PTCT in Q3 2013 and held it in 10 quarters. The position peaked at $40.6M in Q1 2015. 119 funds tracked by Wall St. Rank hold PTCT as of Q1 2016.

  • Janus Henderson Investors US reported no remaining PTC Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Janus Henderson Investors US sold 722,415 PTC Therapeutics shares in Q1 2016, an estimated $23.4M.
  • Janus Henderson Investors US first reported a position in PTC Therapeutics in Q3 2013 and held it in 10 quarters.
  • Janus Henderson Investors US's PTC Therapeutics position peaked at $40.6M in Q1 2015.
  • 119 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2016.

Based on Janus Henderson Investors US's 13F filing for Q1 2016, filed 16 May 2016.